These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 29211298)
1. Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study. Vaarwerk B; van der Lee JH; Breunis WB; Orbach D; Chisholm JC; Cozic N; Jenney M; van Rijn RR; McHugh K; Gallego S; Glosli H; Devalck C; Gaze MN; Kelsey A; Bergeron C; Stevens MCG; Oberlin O; Minard-Colin V; Merks JHM Cancer; 2018 Mar; 124(5):1016-1024. PubMed ID: 29211298 [TBL] [Abstract][Full Text] [Related]
2. Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology. Stewart RJ; Martelli H; Oberlin O; Rey A; Bouvet N; Spicer RD; Godzinski J; Stevens MC; J Clin Oncol; 2003 Mar; 21(5):793-8. PubMed ID: 12610176 [TBL] [Abstract][Full Text] [Related]
3. [The treatment results in children with malignant mesenchymal tumors according to the protocols of the International Society of Pediatric Oncology (SIOP)]. López Pérez J; Melero Moreno C; Vivanco Martínez JL; Torres Valdivieso MJ; Cela de Julián E An Esp Pediatr; 1996 Jun; 44(6):557-60. PubMed ID: 8849098 [TBL] [Abstract][Full Text] [Related]
4. Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group. Rosenberg AR; Anderson JR; Lyden E; Rodeberg DA; Wolden SL; Kao SC; Parham DM; Arndt C; Hawkins DS Eur J Cancer; 2014 Mar; 50(4):816-23. PubMed ID: 24361229 [TBL] [Abstract][Full Text] [Related]
5. Nonparameningeal head and neck rhabdomyosarcoma in children and adolescents: Lessons from the consecutive International Society of Pediatric Oncology Malignant Mesenchymal Tumor studies. Orbach D; Mosseri V; Gallego S; Kelsey A; Devalck C; Brenann B; van Noesel MM; Bergeron C; Merks JH; Rechnitzer C; Jenney M; Minard-Colin V; Stevens M Head Neck; 2017 Jan; 39(1):24-31. PubMed ID: 27459057 [TBL] [Abstract][Full Text] [Related]
6. Conservative approach in localised rhabdomyosarcoma of the bladder and prostate: results from International Society of Paediatric Oncology (SIOP) studies: malignant mesenchymal tumour (MMT) 84, 89 and 95. Jenney M; Oberlin O; Audry G; Stevens MC; Rey A; Merks JH; Kelsey A; Gallego S; Haie-Meder C; Martelli H Pediatr Blood Cancer; 2014 Feb; 61(2):217-22. PubMed ID: 23997024 [TBL] [Abstract][Full Text] [Related]
7. Adherence to Treatment, Response and Patterns of Failure in Pediatric Parameningeal Rhabdomyosarcoma: Experience From a Tertiary Cancer Care Center From India. Roy S; Pathy S; Mohanti BK; Chander S; Biswas A J Pediatr Hematol Oncol; 2017 Mar; 39(2):e62-e68. PubMed ID: 28060113 [TBL] [Abstract][Full Text] [Related]
8. Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors Committee. Rodeberg DA; Anderson JR; Arndt CA; Ferrer FA; Raney RB; Jenney ME; Brecht IB; Koscielniak E; Carli M; Bisogno G; Oberlin O; Rey A; Ullrich F; Stevens MC; Meyer WH Int J Cancer; 2011 Mar; 128(5):1232-9. PubMed ID: 20473932 [TBL] [Abstract][Full Text] [Related]
9. The impact of surgical excision in chest wall rhabdomyosarcoma: a report from the Children's Oncology Group. Hayes-Jordan A; Stoner JA; Anderson JR; Rodeberg D; Weiner G; Meyer WH; Hawkins DS; Arndt CA; Paidas C; J Pediatr Surg; 2008 May; 43(5):831-6. PubMed ID: 18485948 [TBL] [Abstract][Full Text] [Related]
10. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. Meza JL; Anderson J; Pappo AS; Meyer WH; J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036 [TBL] [Abstract][Full Text] [Related]
11. Relationship between tumor response at therapy completion and prognosis in patients with Group III rhabdomyosarcoma: A report from the Children's Oncology Group. Lautz TB; Chi YY; Tian J; Gupta AA; Wolden SL; Routh JC; Casey DL; Dasgupta R; Hawkins DS; Rodeberg DA Int J Cancer; 2020 Sep; 147(5):1419-1426. PubMed ID: 32012255 [TBL] [Abstract][Full Text] [Related]
12. Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Burke M; Anderson JR; Kao SC; Rodeberg D; Qualman SJ; Wolden SL; Meyer WH; Breitfeld PP; J Clin Oncol; 2007 Nov; 25(31):4909-13. PubMed ID: 17971587 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group. Rodeberg DA; Stoner JA; Hayes-Jordan A; Kao SC; Wolden SL; Qualman SJ; Meyer WH; Hawkins DS J Clin Oncol; 2009 Aug; 27(22):3705-11. PubMed ID: 19470937 [TBL] [Abstract][Full Text] [Related]
14. Localized vaginal/uterine rhabdomyosarcoma-results of a pooled analysis from four international cooperative groups. Minard-Colin V; Walterhouse D; Bisogno G; Martelli H; Anderson J; Rodeberg DA; Ferrari A; Jenney M; Wolden S; De Salvo G; Arndt C; Merks JHM; Gallego S; Schwob D; Haie-Meder C; Bergeron C; Stevens MCG; Oberlin O; Hawkins D; Pediatr Blood Cancer; 2018 Sep; 65(9):e27096. PubMed ID: 29781567 [TBL] [Abstract][Full Text] [Related]
15. Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98. McDowell HP; Foot AB; Ellershaw C; Machin D; Giraud C; Bergeron C Eur J Cancer; 2010 Jun; 46(9):1588-95. PubMed ID: 20338746 [TBL] [Abstract][Full Text] [Related]
16. Primary chemotherapy in rhabdomyosarcomas and other malignant mesenchymal tumors of the orbit: results of the International Society of Pediatric Oncology MMT 84 Study. Rousseau P; Flamant F; Quintana E; Voute PA; Gentet JC J Clin Oncol; 1994 Mar; 12(3):516-21. PubMed ID: 7509854 [TBL] [Abstract][Full Text] [Related]
17. Local therapy is critical in localised pelvic rhabdomyosarcoma: experience of the International Society of Pediatric Oncology Malignant Mesenchymal Tumor (SIOP-MMT) committee. Réguerre Y; Martelli H; Rey A; Rogers T; Gaze M; Ben Arush MW; Devalck C; Oberlin O; Stevens M; Orbach D Eur J Cancer; 2012 Sep; 48(13):2020-7. PubMed ID: 22154650 [TBL] [Abstract][Full Text] [Related]
18. Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a randomized phase 3 clinical trial. Peng H; Chen L; Li WF; Guo R; Mao YP; Zhang Y; Guo Y; Sun Y; Ma J Cancer; 2017 May; 123(9):1643-1652. PubMed ID: 28001301 [TBL] [Abstract][Full Text] [Related]
19. Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee. Orbach D; Rey A; Oberlin O; Sanchez de Toledo J; Terrier-Lacombe MJ; van Unnik A; Quintana E; Stevens MC J Clin Oncol; 2005 Jul; 23(19):4363-71. PubMed ID: 15994146 [TBL] [Abstract][Full Text] [Related]
20. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III. Wolden SL; Anderson JR; Crist WM; Breneman JC; Wharam MD; Wiener ES; Qualman SJ; Donaldson SS J Clin Oncol; 1999 Nov; 17(11):3468-75. PubMed ID: 10550144 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]